2015 American Society of Clinical Oncology Annual Meeting*

May 29-June 2, 2015; Chicago, Illinois
This program provides coverage of the 2015 ASCO annual meeting with downloadable slidesets and expert analysis of the most clinically relevant study results. Topics include solid tumors, hematologic malignancies, and immunotherapy.
Michael Atkins Headshot
Michael B. Atkins, MD
Thomas H. Cartwright, MD
person default
Sagar Lonial, MD
David F. McDermott, MD
Daniel P. Petrylak, MD
person default
Farhad Ravandi, MD
Antoni Ribas, MD, PhD
person default
Naiyer Rizvi, MD
Jeff P. Sharman, MD
Julie M. Vose, MD, MBA
person default
Heather Wakelee, MD

Hematologic Malignancies

Investigators found 3 distinct stem cell phenotypes in AML with no leukemia-free survival at 2 years in those with ALDHhigh phenotype without a bone marrow transplant.

Released: June 5, 2015

Inheritance of a lower number of activating KIR genes in NK cells associated with increased risk of developing high-risk MDS.

Released: June 5, 2015

Doses of gilteritinib ≥ 80 mg showed an ORR of 58% in patients with relapsed/refractory AML and the FLT3 mutation.

Released: June 5, 2015

CD19-targeted 19-28ζ CAR T-cell therapy produced a high CR rate in adult patients with relapsed/refractory ALL.

Released: June 5, 2015

Results of an open-label phase III trial investigating the safety and efficacy of adding idelalisib to ofatumumab in pretreated CLL.

Released: June 5, 2015

Results of a prospectively designed meta-analysis of a new surrogate endpoint that may expedite patient access to effective new therapies.

Released: June 5, 2015

In patients with previously untreated high-intermediate–risk or high-risk DLBCL, brentuximab vedotin + R-CHOP was associated with a response rate of 80%.

Released: June 5, 2015

Results from a randomized phase III trial investigating the addition of the mAB elotuzumab to lenalidomide and dexamethasone in patients with relapsed/refractory MM.

Released: June 5, 2015

Results from the first head-to-head phase III trial comparing 2 proteasome inhibitors in multiple myeloma.

Released: June 5, 2015

Phase II study evaluating induction regimen of KRd, followed by ASCT, KRd consolidation, and maintenance in newly diagnosed multiple myeloma.

Released: June 5, 2015

In this continuation of a phase I/II trial, the optimized dose and schedule of panobinostat and carfilzomib was associated with promising responses in relapsed/refractory multiple myeloma.

Released: June 5, 2015

Overall response rates of 50% in DLBCL and 100% in follicular lymphoma; all CRs maintained as of last analysis.

Released: June 5, 2015

Retrospective analysis suggests that subsets of patients with FL may receive suboptimal doses of rituximab.

Released: June 5, 2015

Sagar Lonial, MD; Farhad Ravandi, MD; Jeff P. Sharman, MD; and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

person default Sagar Lonial, MD person default Farhad Ravandi, MD Jeff P. Sharman, MD Julie M. Vose, MD, MBA Physicians: maximum of 2.75 AMA PRA Category 1 Credits Released: August 25, 2015 Expiration: August 24, 2016

In this downloadable slideset, Sagar Lonial, MD, Farhad Ravandi, MD, Jeff P. Sharman, MD, and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

Released: August 25, 2015

New phase III results from the HELIOS trial of ibrutinib plus BR in previously treated CLL/SLL.

Released: June 5, 2015

In this phase III study, pacritinib demonstrated significantly reduced total symptom scores and improved overall survival.

Released: June 5, 2015

The obinutuzumab-containing regimen was associated with a significant reduction in the risk of progression or death compared with bendamustine alone in patients with rituximab-refractory indolent NHL.

Released: June 5, 2015

In this population of patients who had received a median of 5 prior therapies over 5 years and were refractory to most available agents, daratumumab was associated with an ORR of 29%; no patients discontinued due to adverse events.

Released: June 5, 2015

Gastrointestinal Cancers

Addition of SIRT to chemotherapy first-line treatment of metastatic CRC did not improve overall PFS or ORR, but substantially reduced the risk of disease progression in the liver.

Released: June 1, 2015

Highest baseline vitamin D levels associated with OS and PFS improvement regardless of chemotherapy backbone and biologic assignment.

Released: June 1, 2015

The largest cohort ever to examine the effects of aspirin as secondary prevention reveals that aspirin independently reduces the risk of both CRC-specific mortality and all-cause mortality.

Released: June 1, 2015

Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.

Released: June 2, 2015

This slideset covers the final and subgroup results of the INTEGRATE phase II trial of regorafenib in refractory advanced gastroesophageal cancer as presented at the 2015 ASCO meeting.

Released: June 1, 2015

In this pilot study, mFOLFIRINOX and chemoradiation were shown to be tolerable and allowed most patients to go on to resection.

Released: June 3, 2015

In this CME-certified downloadable slideset, Thomas H. Cartwright, MD, reviews key studies on the management of GI cancers. Review the slide notes for Dr. Cartwright’s commentary.

Thomas H. Cartwright, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 31, 2015 Expiration: July 30, 2016

Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.

Released: May 31, 2015

Genitourinary Cancers

This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.

Released: June 4, 2015

Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.

Released: June 5, 2015

Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.

Released: June 5, 2015

Randomized phase II trial results of a Hsp27 inhibitor suggest potential benefit among patients with poor prognostic features at baseline.

Released: June 4, 2015

Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.

Released: June 4, 2015

Results of the first randomized, individualized therapy study in metastatic bladder cancer.

Released: June 4, 2015

Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.

Released: June 4, 2015

Results of the largest controlled trial in metastatic nonclear-cell RCC show different efficacy among the VEGF-TKI and mTOR inhibitor in specific subgroups.

Released: June 4, 2015

Results of a dose amendment to the phase III ASSURE trial; impact on safety and clinical outcome discussed.

Released: June 4, 2015

Mutations in MTOR, TSC1, and TSC2, but not PTEN or PIK3CA, were associated with complete responses to mTOR inhibitors in patients with metastatic RCC.

Released: June 4, 2015

Interesting results of a large randomized, multiarm, multistage trial that indicate a potential change in standard of care.

Released: June 5, 2015

Biopsy study identified an important new histologic subtype, which when combined with SCNC, represents the largest group of AR therapy–resistant patients.

Released: June 5, 2015

A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.

Released: June 5, 2015

David F. McDermott, MD, and Daniel P. Petrylak, MD, provide their analysis of key genitourinary cancer presentations from the 2015 clinical oncology meeting in Chicago.

David F. McDermott, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 13, 2015 Expiration: August 12, 2016

In this downloadable slideset, David F. McDermott, MD, and Daniel P. Petrylak, MD, review key studies presented at the 2015 American Society of Clinical Oncology Annual Meeting relevant to the management of patients with prostate, kidney, or bladder cancers.

Released: August 20, 2015

Lung Cancer

Results of phase II/III trial suggest that Bevacizumab/Pemetrexed/Cisplatin is a new treatment option although increased toxicity is a potential concern

Released: June 2, 2015

In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.

Released: June 1, 2015

Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.

Released: May 31, 2015

AZD9291, a third-generation irreversible EGFR tyrosine kinase inhibitor, demonstrated an ORR of 73% with few grade ≥ 3 adverse events in previously untreated patients with EGFR mutation–positive, advanced NSCLC.

Released: June 1, 2015

Rociletinib, a third-generation EGFR TKI, is active in patients with acquired resistance to previous EGFR TKI therapy as detected by either standard tumor tissue biopsy or a plasma-based assay.

Released: June 2, 2015

Phase II study results suggest dabrafenib plus trametinib have meaningful antitumor activity, manageable safety profile in BRAF V600E–mutated NSCLC.

Released: June 3, 2015

Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.

Released: June 1, 2015

In an interim analysis of atezolizumab as second-line or third-line therapy for advanced NSCLC, clinical efficacy correlated with PD-L1 expression level.

Released: June 2, 2015

Early results from this phase I trial indicate a manageable safety profile along with robust, durable activity with pembrolizumab + ipilimumab in previously treated patients with advanced NSCLC.

Released: June 2, 2015

Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.

Released: May 31, 2015

Naiyer Rizvi, MD, and Heather Wakelee, MD, provide their analysis of key lung cancer presentations from the 2015 clinical oncology meeting in Chicago.

person default Naiyer Rizvi, MD person default Heather Wakelee, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 7, 2015 Expiration: August 6, 2016

In this downloadable slideset of lung cancer clinical trial highlights from the 2015 American Society of Clinical Oncology annual meeting, Naiyer Rizvi, MD, and Heather Wakelee, MD, discuss key immunotherapy studies in NSCLC and SCLC, review targeting of driver mutations, and discuss treatment of mesothelioma.

Released: August 7, 2015

Immunotherapy

Results of this genomic and molecular study suggest that the lack of spontaneous immune infiltration in some melanomas is not due to lack of tumor antigens.

Released: June 3, 2015

Patients with BRAF-mutant melanoma who received treatment with MEDI4736 + trametinib + dabrafenib showed robust immune activation and promising objective response rate.

Released: June 3, 2015

This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.

Released: June 4, 2015

Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.

Released: June 5, 2015

Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.

Released: June 5, 2015

In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.

Released: June 1, 2015

Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.

Released: May 31, 2015

Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.

Released: June 1, 2015

Core faculty, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.

Michael Atkins Headshot Michael B. Atkins, MD David F. McDermott, MD Daniel P. Petrylak, MD Antoni Ribas, MD, PhD person default Naiyer Rizvi, MD person default Heather Wakelee, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: August 25, 2015 Expiration: August 24, 2016

In this downloadable slideset, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.

Released: August 25, 2015

Data from this large phase III trial suggest that the combination of nivolumab + ipilimumab offers better efficacy vs ipilimumab alone, but also better efficacy vs nivolumab alone, particularly for patients whose tumors are low in PD-L1 expression.

Released: June 2, 2015

Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.

Released: May 31, 2015

Results of a phase1/2 study of nivolumab monotherapy in patients with advanced hepatocellular carcinoma reveal encouraging 12 month survival rate

Released: May 31, 2015

Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.

Released: May 31, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?